Sulfated polysaccharides constitute a large and complex group of macromolecules which possess a wide range of important biological properties. Many of them hold promise as new therapeutics, but determination of their blood levels during pharmacokinetic studies can be challenging. Heparin Red, a commercial mix-and-read fluorescence assay, has recently emerged as a tool in clinical drug development and pharmacokinetic analysis for the quantification of sulfated polysaccharides in human plasma. The present study describes the application of Heparin Red to the detection of heparin, a highly sulfated polysaccharide, and fucoidan, a less sulfated polysaccharide, in spiked mouse and rat plasmas. While the standard assay protocol for human plasma matrix gave less satisfactory results, a modified protocol was developed that provides within a detection range 0-10 µg per mL better limits of quantification, 1.1 -2.3 µg per mL for heparin, and 1.7 -3.4 µg per mL for fucoidan. The required plasma sample volume of only 20 µL is advantegous in particular when blood samples need to be collected from mice. Our results suggest that Heparin Red is a promising tool for the preclinical evaluation of sulfated polysaccharides with varying sulfation degrees in mouse and rat models.
Introduction
Sulfated polysaccharides constitute a large and complex group of macromolecules known to possess a wide range of important biological properties. Heparin (scheme 3, left), a naturally occuring, polydisperse polysaccharide belonging to the glycosaminoglycan family, is of tremendous clinical importance as an anticoagulant drug. It has long been known to have biological effects that are unrelated to its anticoagulant activity, and there has been a recent burgeoning of interest in therapeutic applications of heparins and related sulfated polysaccharides beyond anticoagulant activity. [1, 2] Examples of "non-anticoagulant" sulfated polysaccharides in advanced clinical trials include tafoxiparin [3] (a chemically modified heparin, used for the treatment of prolonged labour), sevuparin [4] (a chemically modified heparin, treatment for sickle cell disease), muparfostat [5] (synthetic sulfated pentasaccharide, liver cancer), pixatimod [6] (highly sulfated synthetic tetrasaccharide, solid tumors), roneparstat [7] (chemically modified heparin, advanced multiple myeloma) and ibsolvmir [8] (dextran sulfate, preventing rejection of transplanted pancreatic islet cells in diabetes patients). Many more sulfated polysaccharides that hold promise as new therapeutics are in earlier or later stages of pre-clinical development, as highlighted by recent reviews. [9] [10] [11] [12] For example, algae-derived polysaccharides such as fucoidans (scheme 3, right) have an attractive array of biological activities with potential health benefits. [13] [14] For both clinical and preclinical drug development, pharmacokinetic analysis needs to be considered. A fundamental requirement for understanding the pharmacokinetics of sulfated polysaccharides is the availability of robust analytical methods, in particular for determining the blood levels of the target compound. The structural complexity makes the quantification of sulfated polysaccharides in complex matrices such as blood plasma challenging, in particular if the compounds lack siginificant anticoagulant activity so that the clinically established, indirect heparin assays based on interaction with coagulation factors are not sufficiently sensitive. Methods based on isolation of the sulfated polysaccharides or -if available -enzyme linked immunosorbent assays involve tedious, time consuming multistep protocols and are not first choice for the analysis of large sample numbers in preclinical or clinical trials.
The drawbacks of analytical methods for sulfated polysaccharides have stimulated the development of simple direct detection methods with cationic dyes that change absorbance or fluorescence upon binding of the polyanionic target. [15] Very few such dye-based assays, however, are commercially and widely available to a broad community of researchers and clinicians. Heparin Red is a commercial fluorescent molecular probe for the detection of sulfated polysaccharides in plasma with outstanding sensitivity in the low µg/mL range. [16] It is a polyamine functionalized, red-fluorescent perylene diimide derivative (scheme 1) that strongly binds polyanionic polysaccharides so that aggregation of dye molecules results in contact quenching of fluorescence (scheme 2). [17, 18] Scheme 1. Structure of Heparin Red. The commercial Heparin Red Kit has been applied to the sensitive quantification in human plasma of unfractionated and low-molecular-weight heparins [19] , heparin octa-and decasaccharides [19] , chemically modified heparins including tafoxiparin [19] , heparan sulfate [20] , algae-derived fucoidans [21] , carrageenan [22] and ulvan [22] , and the semisynthetic polysaccharides dextran sulfate [22] and sulfated hyaluronic acid [22] . Heparin Red is used for pharmacokinetic studies in several of the abovementioned clinical trials of sulfated polysaccharide drug candidates. [23] All these applications of Heparin Red have focused so far on the human plasma matrix. For preclinical studies, mice and rats are the most widely used model organisms. Human, mouse and rat plasma differ in protein composition. [24] Human serum albumin, the most abundant plasma protein, shares only about 70% amino acid sequence homology with mouse and rat albumin. [25] Consequently, binding of small molecules and drugs to albumin and other plasma proteins can differ significantly between human and animal species. [26] Another particularity is the small body size and limited blood volume of rats and especially mice. Quantitative assays for drug exposure that require large blood or plasma sample volumes may not comply with animal welfare guidelines. [27] The present study describes for the first time the application the Heparin Red to the detection of sulfated polysaccharides in mouse and rat plasma. Since response of Heparin Red depends on charge density (sufation degree, respectively) and the polysaccharides species in preclinical development cover a range of charge densities, we have selected as analytical targets heparin, a highly sulfated polysaccharide having an averaged charge of about -1.8 per monosaccharide (scheme 3), and a fucoidan with -0.8 per monosaccharide, representing the less sulfated polysaccharides.
Scheme 3.
Left: Structure of the major repeating disaccharide unit of heparin. The averaged charge density per monosaccharide is typically -1.8. [28, 29] Right: Repeating sulfated fucose unit, as present in many fucoidans. Sulfation pattern is variable, fucose may be monosulfated, disulfated or nonsulfated. The averaged charge density per monosaccharide of the fucoidan used in this study (from the brown algae species F. vesiculosus) is typically -0.8. [14, 21] 
Materials and Methods

Instrumentation
Fluorescence measurements
Sulfated polysaccharides
Unfractionated heparin sodium salt from porcine intestine mucosa ("heparin"), was sourced as a solid from Sigma-Aldrich GmbH, Steinheim (product number H5515, Lot SLBK0235V, indicated potency 210 IU/mg). Fucoidan from from Fucus vesiculosus, purity >95%, product number F8190, Lot SLBN8754V, was purchased from Sigma-Aldrich GmbH, Steinheim. 
Plasma
Methods
Heparin Red® Kit
Heparin, standard protocol (figure 1, 2; table 1)
For determination of heparin in plasma samples, the protocol of the provider for a 96-well microplate assay was followed with a minor modification: The mixture of Heparin Red solution and Enhancer solution was freshly prepared in 1:90 ratio (100 µL + 9 mL).
Heparin, protocol with added MgCl 2 (figure 3, 4; table 2)
As above, but the freshly prepared reagent mixture was 8.775 mL Enhancer solution + 225 µL aqeous MgCl 2 solution + 100 µL Heparin red solution. All assays were continued as recommended by the protocol of the provider: 20 µL of the heparin or fucoidan spiked plasma sample was pipetted into a microplate well, followed by 80 µl of the Heparin Red -Enhancer (MgCl 2 ) mixture. For sample numbers > 10, a 12-channel pipette was used for addititon of the Heparin Red -Enhancer (MgCl 2 ) mixture. The microplate was introduced in the fluorescence reader and shaken for 3 minutes, using plate shaking function of the reader (setting "high"), followed by fluorescence measurement within 1 minute.
Preparation of spiked plasma samples
Plasma samples containing defined concentrations of heparins were prepared as follows:
Aqueous solutions (2 vol%) of unfractionated heparin and fucoidan, respectively, were added too pooled human plasma to achieve a concentration of 10 µg/mL. Concentrations required for the detections were adjusted by further dilution of this 10 µg/mL stock solution with the same plasma. The spiked plasma samples were stored at -20°C and thawed at room temperature before use.
Data analysis
Data were analyzed using Excel (Microsoft Office 10). Linear regression "through origin" ( with y-intercept set to 1) was applied to the response curves in figure 2, 4, 6 and 8.
Coefficients of determination (r 2 ) in table 1-4 were determined by linear regression.
Results and discussion
Quantification of unfractionated heparin in mouse, rat and human plasma
In a first series of measurements, the Heparin Red Kit was applied to the determination of heparin in spiked plasma matrices (mouse, rat1, rat2 and human) by following the standard protocol recommended by the provider. The fluorescence response of Heparin Red is shown in figure 1 . Obviously, the fluorescence of Heparin Red in the heparin-free rodent plasmas is much lower compared with human plasma. This could be related to association of Heparin Red with a plasma component of the rodent plasmas that is not prevalent in human plasma, leading to fluorescence quenching. While the response curves for mouse and rat1 plasma are almost overlapping, the difference between the plasmas rat1 (not lyophilized; Sprague Dawley rats) and rat2 (lyophilized and reconstituted; mixture of strains) is quite significant. The detection and quantification limits for the different plasma matrices (table 1) were determined based on signal-to-noise [32] , by relating extrapolated response (linear regression "through origin" for the concentration range 0-6 µg/mL) to the standard deviation of blank samples (σ blank ) without heparin. The limit of detection (LOD) was calculated as LOD = 3 σ blank / S (S= initial slope of response curve, see figure 2 ) and the limit of quantification as LOQ = 10 σ blank / S. Table 1 . σblank, coefficient of determination (r 2 ), limit of detection (LOD) and limit of quantification (LOQ) for heparin in four different plasma matrices, relating to the data in figure 2 . σblank is the standard deviation of the normalized optical signal generated by the heparin-free plasma samples. r Table 2 . σblank, coefficient of determination (r 2 ), limit of detection (LOD) and limit of quantification (LOQ) of heparin four different plasma matrices, relating to the data in figure 4 (modified protocol).
Plasma
σblank is the standard deviation of the normalized optical signal generated by the heparin-free plasma samples. r 2 is the coefficient of determination obtained from linear regression (figure 4). LOD = 3 σblank / S (S= slope of response curve, see figure 4 ). LOQ = 10 σblank / S.
Quantification of fucoidan in mouse, rat und human plasma
Fucoidan from the brown alga Fucus vesiculosus has a lower averaged charge density per monosaccharide than heparin, -0.8 vs -1.8 (scheme 3). The weaker binding of Heparin Red to less highly charged polysaccharides leads to a diminished response relative to heparin in the competitive human plasma matrix. [20, 21, 34] The reduced sensitivity toward fucoidan in human plasma can be counteracted by a minor modification of the standard protocol, so that a similar concentration range as for heparin can be addressed. This modified protocol [21] uses a lower Heparin Red concentration (see "Materials and Methods" for details) and has also been applied to fucoidan detection in the present study. Otherwise, fucoidan determination in the different plasma matrices was performed and evaluated as described above for heparin. Table 3 . σblank, coefficient of determination (r 2 ), limit of detection (LOD) and limit of quantification (LOQ) for fucoidan in four different plasma matrices, relating to the data in figure 6 . σblank is the standard deviation of the normalized optical signal generated by the heparin-free plasma samples. r (table 4 vs table 3 ) for fucoidan detection is present but less pronounced than for heparin detection (table 2 vs table 1 ). Table 4 . σblank, coefficient of determination (r 2 ), limit of detection (LOD) and limit of quantification (LOQ) for fucoidan in four different plasma matrices, relating to the data in figure 8 . σblank is the standard deviation of the normalized optical signal generated by the fucoidan-free plasma samples. r 
Conclusion
This study addresses the need for simple and user-friendly analytical methods for quantifying the blood levels of sulfated polysaccharides in mice and rats in the context of preclinical drug development. The commercially available, direct fluorescence assay Heparin
Red was applied to the quantification of heparin, a highly sulfated polysaccharide, and fucoidan, a less sulfated polysaccharide, in spiked mouse and rat blood plasma samples.
Application of a standard protocol for human plasma resulted in poorer detection sensitivities for the rodent plasma matrices. Quantification limits (LOQs) for both target analytes could be improved significantly by simple modifications of the protocol, in particular by the addition of magnesium chloride to the assay mixture. The improved protocol provides within the detection range 0-10 µg/mL the LOQs 1.1 -2.3 µg/mL for heparin, and 1.7 -3.4 µg/mL for fucoidan (LOQ is defined as 10 σ blank / S, σ blank being standard deviation of blank and S the initial slope of response curve). The low plasma sample volume of only 20 µL is advantegous in particular when blood samples are collected from mice.
Heparin Red is a promising tool for the preclinical evaluation of sulfated polysaccharides that hold promise as new therapeutics. Polysaccharides of varying sulfation degrees are determined at low µg/mL levels in mouse and rat plasma by a simple mix-and-read microplate assay. 
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